key: cord-0714156-jkyemcau
authors: Giamarellos-Bourboulis, Evangelos J.; Poulakou, Garyfallia; de Nooijer, Aline; Milionis, Haralampos; Metallidis, Simeon; Ploumidis, Michalis; Grigoropoulou, Pinelopi; Rapti, Aggeliki; Segala, Francesco Vladimiro; Balis, Evangelos; Giannitsioti, Efthymia; Rodari, Paola; Kainis, Ilias; Alexiou, Zoi; Focà, Emanuele; Lucio, Brollo; Rovina, Nikoletta; Scorzolini, Laura; Dafni, Maria; Ioannou, Sofia; Tomelleri, Alessandro; Dimakou, Katerina; Tzatzagou, Glykeria; Chini, Maria; Bassetti, Matteo; Traketelli, Christina; Tsoukalas, George; Selmi, Carlo; Samaras, Charilaos; Saridaki, Maria; Pyrpasopoulou, Athina; Kaldara, Elisabeth; Papanikolaou, Ilias; Argyraki, Aikaterini; Akinosoglou, Karolina; Koupetori, Marina; Panagopoulos, Periklis; Dalekos, George N.; Netea, Mihai G.
title: Development and validation of SCOPE score: a clinical score to predict progression of COVID-19 pneumonia to severe respiratory failure
date: 2022-02-25
journal: Cell Rep Med
DOI: 10.1016/j.xcrm.2022.100560
sha: 65312dec270f79a34215e259c4bab0905bb3c1ae
doc_id: 714156
cord_uid: jkyemcau

Most patients infected with SARS-CoV-2 (COVID-19) experience mild, non-specific symptoms, but several develop severe symptoms associated with an excessive inflammatory response. Elevated plasma concentrations of soluble urokinase plasminogen activator receptor (suPAR) provide early warning of progression to severe respiratory failure (SRF) or death, but access to suPAR testing may be limited. The Severe COvid Prediction Estimate (SCOPE) score, derived from C-reactive protein, D-dimers, interleukin-6, and ferritin circulating concentrations among patients not receiving non-invasive or invasive mechanical ventilation during the SAVE-MORE study, offers comparable predictive accuracy for progression to SRF or death within 14 days as suPAR ≥6 ng/ml (area under receiver operator characteristic curve, 0.81 for both). SCOPE score is validated in two similar independent cohorts. SCOPE score 6 or more is an alternative to suPAR for predicting progression to SRF or death within 14 days of hospital admission for pneumonia, and it can be used to guide treatment decisions.

Most patients infected with SARS-CoV-2 (COVID-19) experience mild, nonspecific symptoms that are generally limited to malaise, fever, and a dry cough. 1 However, several patients experience more severe symptoms, such as dyspnea and hypoxia, and enter into an excessive inflammatory response phase. 1,2 These patients may require hospitalization for pneumonia, and a subset will progress to severe respiratory failure (SRF), which is associated with hyperinflammation characterized by excessively elevated levels of cytokines, chemokines and other inflammatory mediators, including markers of coagulopathy such as D-dimers. 2 As patients may quickly deteriorate, early identification of those at risk for progression to severe disease is crucial for timely initiation of targeted interventions that may prevent progression to SRF and reduce mortality. The SAVE-MORE trial is such an example in which biomarker-based patient stratification can lead to timely and personalized immunotherapy. Patients with COVID-19 pneumonia without signs of SRF and plasma concentrations of the biomarker suPAR (soluble urokinase plasminogen activator receptor) 6 ng/ml or more received early treatment with anakinra (recombinant interleukin-1 receptor antagonist) for 10 days. This strategy had lower odds of a poor outcome (odds ratio 0.36) compared to placebo. Clinical benefit was found towards decreased mortality, prevention of admissions in the intensive care unit, and increase of infection resolution. 3 The results of the SAVE-MORE trial were the backbone for the approval of anakinra for the therapy of COVID-19 pneumonia in adults by the European Medicines Agency. 4 Elevated plasma concentrations of suPAR provide early warning of activation of the inflammatory and coagulation pathways, and of endothelial-neutrophil interaction, prior to the development of the clinical signs and symptoms of J o u r n a l P r e -p r o o f hyperinflammation. 5, 6 suPAR levels at the time of admission have been found to be prognostic of patients progressing to SRF after being hospitalized for COVID -19 pneumonia. 3, [7] [8] [9] [10] [11] [12] However, in hospital settings where rapid suPAR testing may not be routinely available, 13 an alternative biomarker or combination of biomarkers based on routinely collected laboratory parameters is necessary to help readily identify patients with COVID-19 pneumonia who are at greatest risk of progressing to SRF.

As part of the randomized controlled phase 3 SAVE-MORE trial, data were collected during screening on biomarkers that reflected inflammation, coagulation, and endothelial activation. 3 These biomarkers -C-reactive protein (CRP), D-dimers, IL-6 and ferritincan be readily obtained in routine clinical practice. Herein, we aimed to investigate the potential of these four biomarkers to be incorporated into a simple scoring system (the Severe COvid Prediction Estimate [SCOPE] score) that could be used as a prognostic marker for progression to SRF or death in patients hospitalized with COVID-19 pneumonia. The SCOPE score was derived using data from patients screened for enrollment in the phase 3 SAVE-MORE study, then validated using two independent cohorts; one cohort collected during the phase 2 SAVE study 11 and another cohort collected in the Netherlands.

The discovery cohort was recruited from the 1060 patients screened for the SAVE-MORE study. None of these patients was receiving non-invasive or invasive mechanical ventilation. Biomarker data were available for 639 (60.3%) patients. Of those patients, 225 patients had plasma suPAR concentrations less than 6 ng/ml and were excluded from SAVE-MORE, while 390 patients with suPAR J o u r n a l P r e -p r o o f concentrations 6 ng/ml or more were enrolled in the study and randomized 2:1 to anakinra or placebo (Figure 1 and Supplementary Table 1 ). An additional 24 patients with suPAR levels 6 ng/ml or more were excluded from SAVE-MORE after failing to meet other eligibility criteria. In total, among the total patients enrolled in the SCOPE score discovery cohort 302 patients who were hospitalized with COVID-19 pneumonia and had both biomarker data and data on progression to SRF or death within 14 days available were analyzed for the primary analysis endpoint i.e. the prognostic performance capacity of the SCOPE score compared to suPAR for the prediction of SRF or death the first 14 days. Among these 302 patients, 128 patients had suPAR ≥6 ng/ml and participated in the SAVE-MORE trial being treated with standard-of-care (SoC) and placebo, while 174 patients had suPAR less than 6 ng/ml and were not included in the randomization for the SAVE-MORE trial and were treated with SoC; 14-day outcome data were available for all these 302 patients. All patients were analyzed for the two secondary endpoints i.e. the ability of the SCOPE score to predict suPAR 6 ng/ml or more and the response to treatment with anakinra for patients scoring positive by the SCOPE score. Plasma samples used for the measurement of the four biomarkers were collected at the time of screening for inclusion at the SAVE-MORE trial: they were the same samples in which suPAR was measured for screening.

Two validation cohorts of patients with similar severity not receiving noninvasive or invasive mechanical ventilation were also studied. Validation cohort I was recruited from patients who were screened for eligibility for the SAVE study and their comparators. SAVE study is an on-going phase 2 open-label, non-randomized trial using the same inclusion and exclusion criteria as the SAVE-MORE trial. An interim analysis of this study was published; 11 since then 1107 patients have been screened J o u r n a l P r e -p r o o f for eligibility and full biomarker data allowing calculation of the SCOPE score are available in 772 patients. The primary endpoint of the analysis was validated in 153 comparators with suPAR levels 6 ng/ml or more and in 97 patients who failed screening because of suPAR levels less than 6 ng/ml (Figure 1 and Supplementary Patients of the discovery cohort and of both validation cohorts were of European ancestry.

Patients of the discovery cohort with suPAR less than 6 ng/ml were younger and less severe than patients with suPAR 6 ng/ml or more. Most patients were receiving SoC treatment with dexamethasone (Supplementary Table 1 ). SCOPE score was calculated by allocating CRP, ferritin, IL-6, and D-dimer concentrations a score of 0 to 3 points for each biomarker (total score ranging between 0 and 12 points): the specific concentrations that define the points allocated to each biomarker have been defined based on the quartile within the discovery population (see Table 1 that presents the specific concentrations for each biomarker J o u r n a l P r e -p r o o f points). These four biomarkers were selected for inclusion in the score since these were also used to characterize patients included in the SAVE-MORE study following advice by the Emergency Task Force for COVID-19 (COVID-ETF) of the European Medicines Agency (EMA). 3 Area under the receiver operating characteristic curve (AUROC) for predicting progression to SRF or death within 14 days was not significantly different when comparing AUROC for suPAR levels (0.81; 95% confidence interval [CI], 0.75-0.87) or SCOPE score (0.81; 95% CI, 0.75-0.86; pvalue of comparison 1.00) (Figure 2A ). SCOPE score 6 or more had a sensitivity for SRF or death of 89.4% and a negative predictive value of 96.7% using the Youden Index ( Figure 2B ). Four elements of prognostic performance (AUROC, sensitivity, positive predictive value, and negative predictive value) were similar between SCOPE score and suPAR when predicting progression to SRF or death within 14 days (Figures 2C and 2D) . The prognostic performance of each biomarker separately was much poorer than suPAR (Supplementary Figure 1) . Four subscores were also calculated taking into consideration three of the four biomarkers; their prognostic performance was poorer than the SCOPE score (Supplementary In order to better establish the correctness of the selection of these four biomarkers for the development of the SCOPE score, LASSO regression analysis was done. In this analysis, it was shown that even after correction for multiple tests, suPAR was independently and significantly correlated with each of the four biomarkers (Supplementary Figures 4A to 4D) . The four biomarkers did not cluster, indicating their synergism to provide predictive information on suPAR (Supplementary Figure 4E) . This was further proven after multivariate forward step- 

To further investigate the clinical utility of the SCOPE score, the efficacy of anakinra was studied for patients with SCOPE 6 or more. This was done by ordinal regression analysis according to the guidance received by the COVID-ETF of the European Medicines Agency for the analysis of the SAVE-MORE trial using in the multivariate model the co-variates used for stratified randomization. 3 Patients with a SCOPE score ≥6 treated with anakinra had lower odds for worse outcome as 

When applied to patients included in the validation cohort I, the AUROC for SCOPE score ≥6 (0.79; 95% CI, 0.73-0.85) was similar to suPAR ≥6 ng/ml (0.83; 95% CI, 0.77-0.88) for predicting progression to SRF or death within 14 days as were the prognostic characteristics ( Figure 5 and Supplementary Figure 7) . 92.3% of patients with a SCOPE score ≥6 had suPAR levels ≥6 ng/ml (Supplementary Table 3 ). Patients with a SCOPE score ≥6 treated with anakinra had lower odds for worse outcome as defined by the WHO-CPS at day 28 (adjusted odds ratio 0.29 (0.19-0.43; p<0.0001) over comparators (Supplementary Figure 8) . It needs to be underlined that SAVE was an open-label, single-arm trial in which all participants were treated with anakinra. Comparators were patients matched for age, gender and co-morbidities with suPAR 6 ng/ml treated with similar SoC hospitalized in same level of care departments. 11

The sensitivity, specificity, PPV and NPV of suPAR and of the SCOPE score for the prediction of the risk of progression to SRF or death within 14 in the validation cohort II were similar to the discovery cohort and the validation cohort I (Figure 6 ).

The 95.2% of patients with a SCOPE score ≥6 had suPAR levels ≥6 ng/ml (Supplementary Table 4 ).

A suPAR concentration ≥6 ng/ml has been identified as predictive of progression to SRF or death in patients hospitalized with COVID-19 pneumonia. [7] [8] [9] [10] [11] [12] However, use in the clinical setting may be limited by access or low familiarity with the measure preventing the use of anakinra in a population where the medical need has been demonstrated. 13 Here, we show that a SCOPE score 6 or more, defined as a combination of scoring based on circulating concentrations of CRP, IL-6, ferritin and D-dimers (see Table 1 ), offers a readily available, validated, and simple to alternate for suPAR concentrations 6 ng/ml or more so that it can be easily applied in clinical practice. The analyses performed in this study using a discovery cohort and two independent validation cohorts demonstrated that the prognostic characteristics of suPAR levels ≥6 ng/ml and SCOPE score ≥6 for predicting progression to SRF or death within 14 days were similar. In the SAVE and SAVE-MORE trials, suPAR was used as an indicator of patients at risk who should receive anakinra treatment. In the same sense, SCOPE is a score predicting the risk progression into severe respiratory failure and patients scoring 6 or more have lower odds for poor outcome when receiving anakinra treatment. Since the great majority of participants in SAVE and SAVE-MORE trials were receiving SoC containing dexamethasone, the number of participants not treated with dexamethasone was too limited to be able to show an J o u r n a l P r e -p r o o f independent benefit coming from dexamethasone treatment. The ORs for WHO-CPS at day 28 for dexamethasone for patients with SCOPE score 6 or more were similar to those described for the entire SAVE and SAVE-MORE cohorts. 3, 11 One major strength of the SCOPE score is the high negative predictive value which may contribute to triage decision making. It may be argued that IL-6 is not measured in several hospital settings making the calculation of the SCOPE score difficult. Our sub-group analysis (provided at Supplementary Figure 2) showed that by using the same concentrations quartiles of CRP, D-dimers and ferritin a score with similar high negative predictive value may derive. However, that score is lacking the high sensitivity of the SCOPE score.

The composition of the SCOPE score is consistent with previous suggestions that an effective biomarker for predicting progression among patients infected with COVID-19 needs to incorporate hematologic, inflammatory, biochemical, and immunologic parameters. 14 Notably, the SCOPE score has improved prognostic performance compared with each of its single components. Results from a systematic review and meta-analysis of biomarkers suggest that single biomarkers have a relatively modest prognostic performance for predicting poor outcomes for COVID-19 pneumonia compared with a score combining several biomarkers such as SCOPE or a single biomarker reflecting various pathophysiological processes, such as suPAR. 15 Specifically, the meta-analysis found that patients defined as higher risk based on individual biomarkers had an up to 6.33-times greater probability of poor outcomes compared with 6-to 7-times for SCOPE score and 6-to 11-times for suPAR demonstrated here. 15 The rationale of the SCOPE score is to integrate information coming from modest increase of biomarkers of activation of the inflammatory pathway, of the J o u r n a l P r e -p r o o f coagulation pathway and of endothelium, that can be combined into a composite measure informing early for the initiation of risk and for the need to start immune intervention. The majority of enrolled patients in the CORIMUNO-ANA-1 study were under treatment necessity for oxygen supplementation by mask or nasal prongs.

However, these patients were already experiencing high level activation of all the pathways; median ferritin was 1479 ng/ml in the anakinra arm and 1151 ng/ml in the placebo arm; median CRP was 120 mg/l in the anakinra arm and 121 mg/l in the placebo; and median D-dimers were 0.99 mg/l in the anakinra arm and 1.28 mg/l in the placebo arm. The values of each biomarker were within the range of 3 points of the SCOPE score, indicating that the level of activation of all three pathways was already so high that it is most likely that anakinra treatment was started much too late to be able to show any benefit. 16 Other prognostic scores for predicting COVID-19 disease severity and mortality using a combination of biomarkers have also been proposed, but most require data to be collated from more than one source or more complex calculations. 17 In one example of a biomarker combination being associated with an AUROC >0.9, the analysis was limited by the retrospective and single-center nature.

Data derived solely from the Wuhan region of China during the early stages of the COVID-19 pandemic (December 2019-March 2020) without considering the impact of the rapid advances in the SoC during the pandemic which may influence real prognostication. 18 In contrast, the SCOPE score was developed and validated using data from prospectively enrolled cohorts receiving dexamethasone as part of the current SoC. All necessary parameters to calculate the SCOPE score can be measured using a single platform, while still offering an AUROC >0.8.

The need for a score that can early predict the risk for progression into critical illness has been also the aim of other studies during the COVID-19 pandemic. One such effort is the COVID-GRAM score which takes into consideration 10 variables i.e. chest X-ray abnormalities, age, hemoptysis, dyspnea, lack of consciousness, number of co-morbidities, cancer history, neutrophil to lymphocyte ratio, lactate dehydrogenase and direct bilirubin. The score was developed in a cohort of 1,590 patients and it was fully validated in a second cohort of 710 patients. In both cohorts the AUROC of prediction for progression to critical illness was 0.88 19 .

In conclusion, suPAR circulating concentration predicts progression to SRF or death and reflects several underlying biological processes that play an important role in COVID-19 pathophysiology (inflammation, coagulation and endothelial activation).

In the absence of a point-of-care suPAR analysis being widely accessible, 13 a SCOPE score 6 or more was identified and validated as an alternative for suPAR to predict progression to SRF or death within 14 days of hospital admission. This ability to rapidly predict outcomes for patients with COVID-19 pneumonia and to guide treatment accordingly will likely offer a significant clinical benefit. 

We worked to ensure gender balance in the recruitment of human subjects.

We worked to ensure ethnic or other types of diversity in the recruitment of human subjects. While citing references scientifically relevant for this work, we also actively worked to promote gender balance in our reference list. 

Further information and requests for resources and reagents should be directed to and will be fulfilled by the lead contact, Evangelos J. Giamarellos-Bourboulis (egiamarel@med.uoa.gr).

This study did not generate new unique reagents.

Any additional information required to reanalyze the data reported in this work paper is available from the Lead Contact upon request. This paper does not report original code.

The SAVE 11 and SAVE-MORE 3 studies enrolled adult (age ≥18 years) male and female patients with SARS-CoV-2 infection confirmed by molecular testing who were hospitalized, had findings in chest X-rays or chest computed tomography imaging that were consistent with a lower respiratory tract infection, and had a plasma suPAR levels 6 ng/ml or more. Exclusion criteria were: non-invasive or mechanical ventilation, stage IV malignancy, any do-not-resuscitate decision, respiratory ratio PaO2/FiO2 <150 mmHg, severe hepatic failure, any primary immunodeficiency, neutrophils less than 1500/mm 3 

The primary and secondary endpoints were common for all cohorts.

The primary endpoint was the development of the SCOPE score using integrated information from CRP, D-dimers, ferritin and IL-6 to prognosticate the progression into SRF or death after 14 days. SRF was defined as PaO2/FiO2 <150 mmHg necessitating high-flow oxygen or non-invasive ventilation or mechanical ventilation. This analysis included for the discovery cohort patients who failed screening because suPAR was less than 6 ng/ml and patients who were enrolled in the SAVE-MORE study and who were allocated to treatment with SoC and placebo. This analysis included for the validation cohort I patients who failed screening because suPAR was less than 6 ng/ml and comparators with suPAR 6 ng/ml or more who were receiving SoC. This analysis included for the validation cohort II all participants.

The study has two secondary endpoints. The first secondary endpoint was the performance of the SCOPE score to predict suPAR levels 6 ng/ml or more. This analysis comprised patients of all cohorts with suPAR 6 ng/ml or more. The second secondary endpoint was the clinical efficacy of anakinra treatment for patients scoring positive for the SCOPE score as this is defined by the distribution of frequencies of the 11-point WHO-CPS. This analysis included for the discovery cohort those of patients with available SCOPE score who were allocated to treatment with SoC and placebo or with SoC and anakinra. This analysis included for the validation cohort I those of patients with available SCOPE score who were treated with SoC and anakinra and comparators who were treated with SoC. This analysis could not be done for the validation cohort II since no patient was treated with anakinra.

The analysis of the primary endpoint of the performance of suPAR and SCOPE score for predicting progression to SRF or death was done by receiver operator curve (ROC) analysis providing the area under the curve (AUCROC) and 95% confidence intervals (CIs). The best trade-off for sensitivity and specificity of the coordinate points of ROC of SCOPE was defined by applying the Youden index.

Sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) were calculated by a 2x2 table. The odds ratio (OR) and 95% CIs of the selected cut-off was determined using the Mantel-Haenszel test. The AUROC of single suPAR, of single SCOPE score and of the combination of suPAR and SCOPE score were compared by the Vassar stats formula (https://www.google.com/search?client=firefox-b-d&q=comparison+of+two+roc+curves+vassar); sensitivities, specificities, PPVs and NPVs of suPAR 6 ng/ml or more and of the selected SCOPE score cut-off for the prediction of SRF or death the first 14 days were compared by the Fisher's exact test. The odds ratios and 95% CI were calculated by Mantel Haenszel's statistics.

Cox regression analysis was done to define if SCOPE score was an independent predictor of progression to SRF or death the first 14 days. Variables also included in the step-wise Cox regression model were suPAR 6 ng/ml or more, pneumonia WHO severity, intake of dexamethasone and BMI more than 30 kg/m 2 ; hazard ratio (HR) and 95% CI were defined.

The analysis of the first secondary endpoint was done using a 2 x 2 table and Fisher exact test. Non-parametric correlation between SCOPE score and suPAR was done according to Spearman's rank of order. The analysis of the second secondary endpoint was done using multivariate ordinal regression analysis.

The selection of the four biomarkers for inclusion in the SCOPE score was further confirmed by LASSO regression analysis in two steps. At the first step, suPAR was correlated to each of the four biomarkers using Spearman's rank of order and after applying correction of the p-values for multiple tests. At the second step, forward step-wise multivariate logistic regression analysis was done with suPAR 6 ng/ml or more as a binary dependent variable. The quartiles of CRP, Ddimers, ferritin and IL-6 used for the development of the SCOPE score in the discovery set entered the model as independent variables. The ORs and 95%CIs were calculated.

Any p-value below 0.05 was considered statistically significant.

J o u r n a l P r e -p r o o f Table 1 The SCOPE score Each of the four biomarkers is allocated 0 to 3 points according to the concentration.

The final score is the addition of the points provided by each biomarker. The comparison includes patients enrolled in the SAVE-MORE trial and randomized to treatment with standard-of-care (SoC) and placebo (n=128) and patients who were screened for enrolment in the SAVE-MORE trial and who were NOT enrolled because suPAR was less than 6 ng/ml (n=174); all patients with suPAR less than 6 ng/ml received SoC treatment.

A) Time to progression into SRF or death the first 14 days when suPAR is 6 ng/ml or more and when suPAR is less than 6 ng/ml. 

COVID-19: unravelling the clinical progression of nature's virtually perfect biological weapon

COVID-19 illness in native and immunosuppressed states: A clinical-therapeutic staging proposal

Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial

suPAR: The unspecific marker for disease presence, severity and prognosis

Interaction of high-molecular-weight kininogen with endothelial cell binding proteins suPAR, gC1qR and cytokeratin 1 determined by surface plasmon resonance (BiaCore)

Biomarkers associated with COVID-19 disease progression

Biomarkers and outcomes of COVID-19 hospitalisations: systematic review and meta-analysis

Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): a randomised controlled trial

Prediction models for diagnosis and prognosis of covid-19: systematic review and critical appraisal

Clinical value of laboratory indicators for predicting disease progression and death in patients with COVID-19: a retrospective cohort study

Development and validation of a clinical risk score to predict the occurrence of critical illness in hospitalized patients with COVID-19

 SCOPE score is composed by C-reactive protein, D-dimers, ferritin and interleukin-6  Values 6 or more predict 6-fold risk for severe respiratory failure or death  SCOPE score prognoses risk for severe respiratory failure or death similar to suPAR  Anakinra treatment when SCOPE is 6 or more provides less odds for poor pneumonia. This is composed by C-reactive protein, D-dimers, ferritin and interleukin-6. Anakinra treatment administered when SCOPE is 6 or more provides less odds for poor outcome.